Cohort 2 recruited 100 healthy infants at the Post Graduate Insti

Cohort 2 recruited 100 healthy infants at the Post Graduate Institute

of Medical Education and Research (PGIMER), Chandigarh and Institute of Child Health (ICH), Kolkata. In Cohort 1, 20 healthy Indian adult volunteers between 18 and 55 years of age were randomized into two groups (3:1) to receive a single 2.0 mL oral dose of either a ready to administer liquid formulation of BRV-TV (106.4 FFU per serotype per dose) or placebo. In Cohort 2, 100 healthy infants were equally randomized into five study groups (1:1:1:1:1), Groups A–E. Group A received three doses of placebo (2.0 mL each), Groups B, C and D received three doses of BRV-TV (2.0 mL each) at one of the antigen concentrations (105.0 FFU, 105.8 FFU and 106.4 Afatinib research buy FFU per serotype per dose respectively) and Group E received three doses of Rotateq (2.0 mL each). The vaccines/comparator/placebo

were administered at 6–8, 10–12 and 14–16 weeks of age in Cohort 2. The study was conducted following regulatory approval from Nutlin-3a ic50 the Indian National Regulatory Authority, the Drug Controller General (India) (DCGI) and ethical clearances from the ethics committees of all the three study sites. Written informed consents were obtained from each volunteer in Cohort 1 and from each infant’s parent/guardian in Cohort 2 before entry into the study. The investigational vaccine (BRV-TV) used in the study was the live attenuated Tetravalent Bovine-Human Reassortant Rotavirus (G1, G2, G3 and G4) vaccine (ready to administer liquid formulation). The product was a single component Dichloromethane dehalogenase product containing a mixture of Rotavirus (Tetravalent) vaccine strains, excipients and buffer. The vaccine contains four virus serotypes of G1, G2, G3 and G4 at equal titre in Minimal Essential Medium, formulated

with stabilizers and buffers. The placebo preparation had the same constituents as the BRV-TV vaccines except for the virus strains. The active comparator Rotateq contained five live human bovine reassortant viruses which has a minimum of 2.0 to 2.8 × 106 Infectious Units (IU) per reassortant dose, depending upon the serotype. All vaccines and placebo, given as three 2.0 mL doses, were administered orally at 28 days interval (Day 0, Day 28 and Day 56) at age 6–8, 10–12 and 14–16 weeks. Infants in Cohort 2 concomitantly received a combined Diphtheria, Tetanus, Whole-cell Bordetella pertussis, Hepatitis B and Haemophilus influenzae type b [DTPwHB-Hib] pentavalent vaccine (Pentavac SD) manufactured by Serum Institute of India, Pune and Trivalent Oral Polio Vaccine (Primopol, Panacea Biotech Limited, New Delhi). Serum IgA antibodies against rotavirus were measured in blood samples obtained before Day 0 (prior to vaccination) and 28 days after each dose of BRV-TV vaccine/RotaTeq/Placebo in cohort 2. An antibody sandwich enzyme immunoassay procedure was used to measure anti-rotavirus IgA in human serum samples [21].

Comments are closed.